IFNA2 and melanoma: Based on these results and the reinforced notion that the combination of immunotherapy and chemotherapy may be beneficial in melanoma because of its immunogenicity, a phase II, multicenter, open, randomized, dose ranging study was performed to investigate the safety and efficacy of different doses of Tα1 in combination with dacarbazine and with or without IFNα in stage IV melanoma (27).